Business Wire

Cognito Therapeutics and Ochsner Health Launch Brain Health Collaboratory to Advance New Care Models for Alzheimer’s Disease

CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...
Business Wire

Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the ...

Cognito Therapeutics Partners with Initiative to Change the "D-Word," Commits to Eliminating Use of "Dementia" Across All Communications

Cognito Therapeutics Partners with Initiative to Change the "D-Word," Commits to Eliminating Use of "Dementia" Across All Communications ...
BioWorld

Know what? Cognito study shows gamma therapy reduces Alzheimer’s biomarkers

A study conducted by Cognito Therapeutics Inc. demonstrated significant changes in white matter volume and myelination in patients with Alzheimer’s disease after six months of at-home, non-invasive ...
Morningstar

Cognito Therapeutics Partners with Initiative to Change the “D-Word,” Commits to Eliminating Use of “Dementia” Across All Communications

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced a partnership with the Initiative ...